The sexual dimorphism of the somatotroph axis has been documented, but whether the acromegaly-related metabolic alterations are gender-dependent has never been investigated.
G
ender may affect the GH and IGF-I secretory pattern both in healthy subjects and in patients with acromegaly through mechanisms not fully understood and with discordant evidence. Spontaneous GH secretion seems to be higher in healthy women than in men (1, 2) , whereas IGF-I levels are similar or higher in men (3, 4) . Due to the lower sensitivity to GH, women affected by GH deficiency or hypopituitarism and receiving estrogen replacement need a higher GH dose than men to achieve normal IGF-I levels (5, 6) . On the other hand, in acromegaly, higher GH or IGF-I levels have been found both in men and in women in different cohorts of patients analyzed. Some authors showed lower serum IGF-I levels and IGF-I/GH ratio in women than in men, particularly in younger patients, without any difference in GH levels, suggesting that gender, presumably sex steroids in women, may only partially modulate the relationship between circulating IGF-I and GH levels in patients with acromegaly (7) . Indeed, Edèn Engströ m et al. (8) demonstrated that women with acromegaly need lower doses of octreotide than men to normalize IGF-I levels.
Conversely, basal GH was found to be higher in de novo women than in men with acromegaly by Colao et al. (9) , and both basal and nadir GH levels were found to be significantly higher in women when GH was measured by different immunoassays (10) . By contrast, a retrospective analysis of the data in the German Acromegaly Register, including 1485 patients, demonstrated significantly higher GH levels in men than women, and sex was considered an independent risk factor for biochemical activity in acromegaly (11) . However, although gender has been considered by some authors a relevant determinant of hormonal levels in acromegaly, crucial to appropriately evaluating the activity of the disease, whether acromegalyrelated metabolic alterations are gender-dependent has not been investigated so far.
The aim of this study was to evaluate the impact of gender on hormonal and metabolic parameters in a large Italian series of newly diagnosed patients with acromegaly.
Patients and Methods

Patients
We retrospectively reviewed the data from consecutive patients with active acromegaly recruited and diagnosed at the Departments of Endocrinology of the Universities of Palermo, Naples, and Genoa between 2000 and 2010. Of 390 newly diagnosed patients, 307 (157 men aged 48 Ϯ 14.2 yr, and 150 women aged 48.6 Ϯ 14.9 yr, of which 77 were premenopausal and 73 were postmenopausal) were included in the study. Exclusion criteria were: mixed GH/prolactin-secreting adenomas, any previous specific treatment for acromegaly (surgery, somatostatin analogs, dopamine agonist, or radiotherapy), and the presence of concomitant overt hypogonadism, to avoid the potential impact of hormonal deficit or gonadal replacement therapy on GH, IGF-I, as well as metabolic parameters. No women receiving estrogens and/or progesterone as contraceptives or postmenopausal hormone in replacement therapy were included. The 157 men and 150 women were divided into the following groups in line with quartiles of age: first quartile (39 men, Ͻ38.5 yr; 41 women, Ͻ37 yr), second quartile (45 men, 38.5-49 yr; 35 women, 37-47 yr), third quartile (38 men, 50 -59 yr; 38 women, 48 -63 yr), and fourth quartile (35 men, Ͼ59 yr; 36 women Ͼ63 yr).
Disease activity at the time of the study was confirmed by altered serum GH during morning profile and/or nonsuppressible GH below 1 g/liter after oral glucose tolerance test (OGTT), elevated age, and gender-corrected plasma IGF-I levels (12) . In 28 subjects with a previous diagnosis of overt diabetes mellitus (DM), OGTT was not performed, and the diagnosis was made by high serum GH, calculated as the mean of a 6-h blood sampling (0800 -1400 h with 30-min sampling), IGF-I levels, and adequate clinical context. As regards hypoglycemic therapy of the whole cohort of patients, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) subjects were treated with diet alone (68%) or metformin (32%); diabetic patients were treated with metformin alone (70%) or in combination with other hypoglycemic drugs (sulfonylureas or glinides) (30%). All patients with a previous diagnosis of DM, IFG, or IGT and already receiving dietary or pharmacological therapy suspended the treatment for at least 3 d before metabolic evaluation to avoid an effect on insulin sensitivity and secretion indexes (13) . In all patients, magnetic resonance imaging revealed the presence of a pituitary tumor. Tumor volume was calculated in line with the Di Chiro and Nelson formula (volume ϭ height ϫ length ϫ width ϫ /6) and was expressed as cubic millimeters. The mean duration of the disease was established by patient interview, patients' clinical pictures, and onset of osteoarticular symptoms. At the time of hospitalization, all patients signed an informed consent for the scientific use of their data. The identity of the participants remained anonymous during database analysis.
Study design
This is a retrospective, comparative, multicenter cohort study. All patients at diagnosis underwent complete clinical and metabolic evaluation. Body mass index (BMI), systolic and diastolic blood pressure were measured in all patients. Waist circumference (WC) was measured at the midpoint between the lower rib and the iliac crest. Patients were analyzed according to each criterion of the metabolic syndrome (MS) (14) and each category of glucose tolerance (15) . After an overnight fast, lipid profile [total, high-density lipoprotein (HDL), and lowdensity lipoprotein-cholesterol, triglycerides], hemoglobin A1c (HbA1c), mean fasting plasma GH (at least three blood samples at 30-min intervals), and IGF-I levels were measured. To normalize IGF-I for age in individual patients, we calculated the ratio between the IGF-I level and the upper limit of the normal (ULN) range for age (normal ϭ Յ1), and the data were presented as IGF-I ULN. OGTT was performed by measuring plasma blood glucose, insulin levels, and GH every 30 min for 2 h after a 75-g oral glucose load. The areas under the curve of glucose (AUC GLU ), insulin (AUC INS ) and GH (AUC GH ) during 2-h OGTT were calculated. Basal insulin resistance was assessed using homeostasis model assessment of the insulin resistance index (Homa-IR) (16) , whereas insulin sensitivity was measured using the insulin sensitivity index (ISI), a composite index derived from the OGTT and validated by Matsuda and DeFronzo (17) . The early insulin-secretion rate was evaluated using the insulinogenic index (18) . The total insulin secretion was assessed by AUC INS , whereas the ␤-cell function relative to insulin sensitivity was assessed by the oral disposition index (DIo) (19) .
As the surrogate of visceral fat function in all patients, we calculated the visceral adiposity index (VAI), an index of adipose tissue distribution and function associated with cardiometabolic risk (20) and already demonstrated to be strongly associated with active acromegaly (21, 22 
Hormone and biochemical assays
Glycemia, HbA1c, and lipid levels were measured in centralized accredited laboratories with standard methods. During the study period, GH levels were assayed by immunoradiometric and immunoenzymatic assays according to availability. The sensitivity of the assays ranged from 0.05-0.02 g/liter. Serum IGF-I was measured using immunoradiometric assays (Diagnostic Systems Laboratories Inc., Webster, TX). The normal ranges The intra-and interassay coefficients of variation were 3.4, 3.0, and 1.5%, and 8.2, 1.5. and 3.7% for low, medium, and high points on the standard curve, respectively. Serum insulin was measured by ELISA (DRG Instruments GmbH, Marburg, Germany). The sensitivity of the method was 1 IU/ml. The normal insulin range (IU/ml) was 5-19. The assays for the assessment of IGF-I and insulin were constant during this entire period. We decided to analyze the data of patients recruited in the decade 2000 -2010 because in that period we did not change assay.
Statistical analysis
The Statistical Packages for Social Sciences SPSS version 17 (SPSS Inc., Chicago, IL) was used for data analysis. Baseline characteristics were presented as mean Ϯ SD for continuous variables; rates and proportions were calculated for categorical data. Normality of distribution for quantitative variables was assessed by the Kolmogorov-Smirnov test. Because age, BMI, and AUC-GLU did not show normal distribution, these variables were logtransformed. Differences between groups in univariate analysis were detected by the unpaired Student's t test for continuous variables and by the 2 test and Fisher's exact test (when appropriate) for categorical variables. Differences in metabolic parameters between men and women were corrected for AUC GH through a logistic regression model. The ANOVA trend analysis was used to assess means of metabolic and hormonal parameters across the age quartiles. A P value of Ͻ0.05 was considered statistically significant.
Results
The clinical and biochemical features of all patients, grouped for gender, are listed in Table 1 ; P ϭ 0.137) was observed between men and women.
Biochemical parameters of acromegaly according to gender
The basal serum GH levels (31. We found a trend toward decrease on basal GH (P Ͻ 0.001 and P ϭ 0.002, respectively), post-OGTT GH nadir (P ϭ 0.001 and P ϭ 0.016, respectively), and AUC GH (P Ͻ 0.001 and P ϭ 0.004, respectively) from the first to the fourth quartile of age in both men and women. In addition, in women a trend toward decrease in tumor volume from the first to the fourth quartile of age (P ϭ 0.013) was found. No significant trend toward variation in IGF-I levels was found in either group (P ϭ 0.170 and P ϭ 0.411 in men and women, respectively). The biochemical parameters of all patients, grouped for quartiles of age, are listed in Tables 2 and 3 for men and women, respectively.
Metabolic parameters of acromegaly according to gender
MS was found in 107 patients (34.9%), and its prevalence was higher in women than in men (51.3 vs. 19.1%; P Ͻ 0.001). Sixty-eight (22.1%) patients had increased WC according to the above-mentioned Adult Treatment Panel III criteria, 57 (38%) of whom were women and 11 (7%) were men (P Ͻ 0.001). Low HDL-cholesterol was found in 120 (39.1%) patients, 93 (62%) of whom were women and 27 (17.2%) were men (P Ͻ 0.001). No gender difference was found in the prevalence of hypertriglyceridemia (31.2 vs. 35.3%; P ϭ 0.443). A total of 107 women and 95 men (71.3 vs. 60.5%; P ϭ 0.046) showed increased systolic blood pressure, whereas no significant difference was found in the prevalence of diastolic blood pressure (46 vs. 40.8%; P ϭ 0.355).
A more marked family history for diabetes was shown in women than in men (48 vs Analyzing the metabolic parameters according to quartiles of age, no significant trend toward variation in all parameters was found in men, with the exception of VAI, which showed a trend toward increase from the first to the fourth quartile (P Ͻ 0.001) (Fig. 1) . Conversely, in women fasting glucose and fasting insulin showed a significant trend toward increase (P Ͻ 0.001) and decrease (P ϭ 0.004), respectively (Fig. 2) . No significant trend toward variation in other metabolic parameters was found, whereas VAI showed a trend toward increase from the first to the fourth quartile (P ϭ 0.001) (Fig. 1) . The metabolic parameters of all patients, grouped for quartiles of age, are listed in Tables 2 and 3 for men and women, respectively.
When we further analyzed each criterion of the MS and the categories of glucose tolerance, grouping women into two groups on the basis of the menopausal status, a significantly higher prevalence of MS (P Ͻ 0.001), increased WC (P Ͻ 0.001), low HDL-cholesterol (P Ͻ 0.001), and overt DM (P Ͻ 0.001) was found in postmenopausal women compared with premenopausal women, as well as with men. Conversely, a slightly higher prevalence of IFG (P ϭ 0.006) was found in men. No significant difference in the prevalence of hypertriglyceridemia (P ϭ 0.683), increased systolic (P ϭ 0.054) and diastolic (P ϭ 0.570) blood pressure, IGT (P ϭ 0.528), and IFG ϩ IGT (P ϭ 0.505) was found among the three groups (Table 4 ). In addition, we compared the metabolic features of acromegalic patients with a group of 301 Caucasian healthy nonacromegalic subjects matched for age and BMI. For this purpose, we used the collected data from Genoa, Naples, and Palermo. Metabolic parameters were significantly poorer in acromegalic patients than in control subjects. Acromegalic men and pre-and postmenopausal women showed a higher prevalence of hypertriglyceridemia, low HDL-cholesterol, increased systolic and diastolic blood pressure, and higher VAI. Acromegalic patients showed a significantly greater prevalence of DM compared with nonacromegalic subjects. A lesser degree of insulin sensitivity was also evident in acromegalic patients regardless of gender, as demonstrated by higher fasting insulin levels and Homa-IR and by lower ISIMatsuda compared with nonacromegalic subjects. These data are shown in Supplemental lished on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org).
Discussion
In this multicenter retrospective study, we analyzed the hormonal and metabolic parameters in a large series of men and women affected by active untreated acromegaly. Women showed a worse metabolic profile than men, regardless of the hormonal data, indicating that gender may independently affect the metabolic parameters in acromegaly.
The sexual dimorphism of the somatotroph axis and the lower sensitivity to GH in women have already been documented (23, 24) , although with discordant results. Higher mean GH concentrations have frequently been found in both healthy and acromegalic women than in men (1, 7, 8) , but these data are not confirmed by other studies (25) . Lower IGF-I levels with concomitant higher GH nadir during OGTT have also been documented in 79 newly diagnosed acromegalic women compared with 72 men (4). In contrast with previous studies, some authors demonstrated higher IGF-I levels in men, because of the potential androgen role in stimulating GH secretion (26) . Our data, showing a similar hormonal profile in men and women in terms of basal GH, nadir of GH during OGTT, AUC of GH and IGF-I levels, are in agreement with those of Freda et al. (27) , which demonstrated in 92 subjects with acromegaly no significant gender difference in basal and nadir GH levels, thus not supporting separate criteria for treatment in men and women with acromegaly.
We found that GH levels showed a similar trend toward decrease from younger to older patients in both sexes, and these data confirm the evidence that in elderly subjects the disease seems to be less aggressive in terms of biochemical parameters. In two previous studies, the severity of acromegaly was reported to be milder in elderly patients than in young ones because it was associated with lower GH values and smaller tumor at presentation (28, 29) . It is known that GH and IGF-I levels physiologically decrease with aging (25, 30) , and our findings are partially in line with those of Colao et al. (4) showing that age is negatively correlated with basal and nadir GH in de novo acromegalic patients of both sexes. We also found that the tumor size did not significantly differ between men and women. In addition, among women, elderly patients had smaller adenomas than young patients. These data are in agreement with previous papers showing the maximal tumor diameter inversely correlated with age in women but not in men (4) .
Beyond the hormonal and tumor parameters, already thoroughly studied, whether the metabolic alterations in acromegaly are dependent on gender has never previously been investigated.
A few years ago, a partial gender dimorphism in body composition abnormalities in acromegaly was hypothesized, with the evidence that acromegalic males had more total mass, lean body mass, and bone mineral content than controls and that the anabolic effect of GH on bone re- verted in cured males but not in females (32) . For these reasons, we aimed to compare all MS features, the categories of glucose tolerance, and all indexes of insulin sensitivity and resistance, grouping the entire cohort of patients according to gender.
The acromegalic women, although displaying GH and IGF-I levels similar to men, showed a worse global metabolic profile, with a higher overall prevalence of MS. We found a lower degree of insulin sensitivity and greater basal and total hyperinsulinism in women than in men, demonstrated by lower ISI-Matsuda and higher fasting and AUC INS levels, regardless of GH levels, whereas no difference was found in early and relative insulin secretion indexes (insulinogenic index and DIo). The BMI, which was comparable between men and women, did not affect these data. A possible explanation can be the higher visceral adipose dysfunction in acromegalic women, shown by higher VAI, than in men. We recently demonstrated that active acromegaly is strongly associated with visceral adiposity dysfunction, and both somatostatin analogs and surgical therapies were able to improve it, as demonstrated by the significant VAI decrease after 12 months of treatment (21) . In addition, patients with high VAI show decreased insulin sensitivity because a significantly strong association between VAI and the rate of peripheral glucose utilization (M value) has been demonstrated (22) . Therefore, the higher VAI levels in women with acromegaly could lead to a lower degree of insulin sensitivity than men. This finding seems to be in contrast with the well-known body composition differences between the sexes in the general population, where men tend to have central fat distribution and women tend to have peripheral fat distribution (33, 34) . The higher visceral adiposity observed in healthy men is associated with elevated postprandial insulin, free fatty acid, and triglyceride levels (35) . Conversely, the peripheral fat distribution typically found in healthy women is associated with improved insulin sensitivity, compared with central fat distribution (36) . According to our results, women with acromegaly seem to have different behavior, in terms of visceral adiposity, compared with the existing data about healthy women. In our previous paper, although patients with high VAI were less insulin-sensitive, no significant difference in the glucose tolerance categories was reported between patients with normal and high VAI, supporting the hypothesis that VAI shows the early signs of metabolic risk, although a significant reduction in glucose tolerance has not yet occurred (22) . This finding is apparently in contrast with these data because women showed a higher prevalence of overt DM. To explain this apparent discrepancy, the role of the higher family history for diabetes shown in women cannot be ruled out. Indeed, a direct and independent influence by family history for diabetes in VAI has already been demonstrated (22) . Conversely, men only showed a higher prevalence of IFG, which disappeared when compared with women grouped according to menopausal status. In this connection, the fact that about half of the women were in the postmenopausal age group must be taken into account. Postmenopausal age in the general population is known to be associated with a higher prevalence of hypertension, diabetes, lipid alterations, and cardiovascular disease, likely due to the coincident increase in insulin resistance and in abdominal adiposity (37) (38) (39) (40) (41) (42) (43) (44) . Accordingly, a majority of postmenopausal women comply with the criteria defining MS, and cardiovascular disease is the first cause of morbidity and mortality in women, occurring even more frequently than in men (45) . Similarly, when we grouped women in line with menopausal status, a higher prevalence of MS, increased WC, low HDL-cholesterol, and overt DM was found in postmenopausal women. Whether these changes are due to aging or to menopause itself is unknown. In this connection, age seems to influence metabolic parameters in acromegaly more in women than in men. The evidence that fasting glucose showed a trend toward increase parallel to age increase in women only, together with a trend toward a decrease in fasting insulin, could be associated with the trend toward increase in VAI from the first to the fourth quartile of age, mainly in women. The visceral adipose dysfunction seems to act on basal insulin secretion and consequently on hepatic glucose output. In this connection, the increase in visceral adipose tissue is reported to contribute to enhanced gluconeogenesis and insulin resistance (46, 47) . Therefore, in agreement with these findings, the higher VAI values in women could explain this different trend in the two groups of patients. In addition, a role of the mammalian target of rapamycin (mTOR) pathway, known to promote hyperinsulinism and insulin resistance and, by a feedback loop, to be overactivated by insulin and other growth factors, cannot be ruled out (48 -50) . In fact, a stronger activation of mTOR signaling in women than in men was recently demonstrated (31) . Therefore, a more pronounced activation of mTOR pathway in women that could favor a greater degree of insulin resistance is not to be ruled out.
In conclusion, these data demonstrated that the majority of metabolic features in acromegaly are gender-specific, regardless of hormonal parameters. Active acromegaly in women is strongly associated with higher visceral adiposity dysfunction, insulin resistance, and the features of MS. Therefore, more careful metabolic management is suggested in acromegalic women. In addition, increased attention to risk factor modification in the postmenopausal years can help prospectively reduce cardiovascular disease risk in women with acromegaly.
